PTC Therapeutics (PTCT) Stock Price, News & Analysis

13 Wall Street analysts have issued "buy," "hold," and "sell" ratings for PTC Therapeutics in the last year. There are currently 5 sell ratings, 5 hold ratings and 3 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "reduce" PTCT shares.
View PTCT analyst ratings or view top-rated stocks.

13 Wall Street research analysts have issued 12-month price targets for PTC Therapeutics' shares. Their PTCT share price targets range from $17.00 to $55.00. On average, they predict the company's stock price to reach $33.53 in the next year. This suggests a possible upside of 32.6% from the stock's current price.
View analysts price targets for PTCT or view top-rated stocks among Wall Street analysts.

PTC Therapeutics' stock was trading at $27.56 at the beginning of 2024. Since then, PTCT stock has decreased by 8.2% and is now trading at $25.29.
View the best growth stocks for 2024 here.

The company is scheduled to release its next quarterly earnings announcement on Thursday, April 25th 2024.
View our PTCT earnings forecast.

PTC Therapeutics will be holding an earnings conference call on Thursday, April 25th at 4:30 PM Eastern. Interested parties can register for or listen to the call using this link.

PTC Therapeutics, Inc. (NASDAQ:PTCT) posted its quarterly earnings data on Thursday, February, 29th. The biopharmaceutical company reported ($0.24) EPS for the quarter, missing the consensus estimate of $0.29 by $0.53. The biopharmaceutical company earned $307.06 million during the quarter, compared to analysts' expectations of $315.90 million.

ETFs with the largest weight of PTC Therapeutics (NASDAQ:PTCT) stock in their portfolio include Morningstar US Small Growth (MSGR), iShares Neuroscience and Healthcare ETF (IBRN), Invesco Biotechnology & Genome ETF (PBE), Virtus LifeSci Biotech Products ETF (BBP), Franklin Genomic Advancements ETF (HELX), Harbor Corporate Culture Small Cap ETF (HAPS), SPDR S&P Biotech ETF (XBI) and Principal Healthcare Innovators ETF (BTEC).

PTC Therapeutics issued an update on its FY 2024 earnings guidance on Thursday, February, 29th. The company provided earnings per share (EPS) guidance of for the period. The company issued revenue guidance of $600.0 million-$680.0 million, compared to the consensus revenue estimate of $612.3 million.

24 employees have rated PTC Therapeutics Chief Executive Officer Stuart W. Peltz on Glassdoor.com. Stuart W. Peltz has an approval rating of 77% among the company's employees.

Based on aggregate information from My MarketBeat watchlists, some companies that other PTC Therapeutics investors own include Baidu (BIDU), Sarepta Therapeutics (SRPT), Alibaba Group (BABA), GW Pharmaceuticals (GWPH), Bausch Health Companies (BHC), NVIDIA (NVDA), Cisco Systems (CSCO), Regulus Therapeutics (RGLS), Aduro Biotech (ADRO) and Gilead Sciences (GILD).

PTC Therapeutics' stock is owned by a variety of institutional and retail investors. Top institutional shareholders include Los Angeles Capital Management LLC (0.01%). Insiders that own company stock include Alethia Young, Allan Steven Jacobson, Christine Marie Utter, David P Southwell, Dawn Svoronos, Emily Luisa Hill, Emma Reeve, Eric Pauwels, Lee Scott Golden, Mark Elliott Boulding, Matthew B Klein, Michael Schmertzler, Neil Gregory Almstead, Pierre Gravier, Stephanie Okey and Stuart Walter Peltz.
View institutional ownership trends.

Shares of PTCT stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.